CDMO

OneSource Pharma targets biologics and drug-device markets with end-to-end solutions and global expansion

Kaushik Gopal Bhattacharaya, Head - Territory Sales Support (Global), Syngene International highlights how outbound leads in the…

Stoffregen will take responsibility for Enzene’s global biologics business and lead the final stages of work to commission the…

Suven has agreed to acquire an initial controlling stake, operate the business together with the selling shareholders for the next…

Aditya Patni, Partner; Achint Kaur and Siddharth Marwah, Counsels at Khaitan & Co decode and decipher factors spurring…

The acquisition of Catalent by Novo Holdings expects to see three new manufacturing sites added to Novo Nordisk’s arsenal, to…

The quarter saw 26 deals totalling $2.7 billion, with a 32 per cent decline in deal volumes compared to Q3 2022

The new R&D centre signals strategic growth plans, expanded capabilities and enhanced services

Our biggest bet is India and the CDMO space, says Nikhil Chopra, CEO, JB Pharma, taking stock of the company's ongoing transition…

Net proceeds planned to be redeployed for debt repayment in accordance with Baxter’s stated capital allocation priorities